Drs. Symmons and Hyrich are principal investigators on the British Society for Rheumatology Biologics Register.
Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies†
Article first published online: 25 FEB 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 3, pages 345–353, March 2010
How to Cite
Saad, A. A., Ashcroft, D. M., Watson, K. D., Symmons, D. P. M., Noyce, P. R., Hyrich, K. L. and British Society for Rheumatology Biologics Register (2010), Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies. Arthritis Care Res, 62: 345–353. doi: 10.1002/acr.20104
The British Society for Rheumatology receives restricted support from UK pharmaceutical companies, currently Abbott Laboratories, Amgen, Schering-Plough, Wyeth Pharmaceuticals, and Roche, which finances a wholly separate contract between the British Society for Rheumatology and the University of Manchester, which provide and run the British Society for Rheumatology Biologics Register data collection, management, and analysis services
- Issue published online: 25 FEB 2010
- Article first published online: 25 FEB 2010
- Manuscript Accepted: 23 OCT 2009
- Manuscript Received: 27 MAR 2009
- UK pharmaceutical companies
- PhD studentship funding from the Egyptian Government
To evaluate the impact of anti–tumor necrosis factor (anti-TNF) therapies on quality of life (QOL) and functional status in psoriatic arthritis (PsA) patients and study potential predictors for QOL improvements.
The study was based on a cohort of 596 PsA patients receiving anti-TNF therapies. Changes in functional status and QOL were assessed using the Health Assessment Questionnaire (HAQ) and Short Form 36 (SF-36) questionnaire on a 6-month basis. The Short Form 6D (SF-6D) was calculated as a utility score. Univariate and multivariate linear regression models were developed to examine potential predictors of QOL improvements at 6 months, using a range of demographic, baseline disease-specific, and therapeutic variables.
At 6 months, significant improvements in all SF-36 subscale scores were found, with the greatest percentage improvement from baseline related to physical role (113.8%; 95% confidence interval [95% CI] 102.6, 125.0). The percent improvement for the physical component scale was 53.2% (95% CI 44.5, 61.9) at 6 months, whereas that for the mental component scale was 16.9% (95% CI 14.7, 19.2). The mean ± SD SF-6D score was 0.58 ± 0.07 at baseline, and this improved to 0.63 ± 0.06 at 6 months. The median HAQ score at baseline was 1.88 (interquartile range [IQR] 1.38–2.25) for the entire cohort, and this improved to 1.25 (IQR 0.63–1.88) at 6 months. Improvements in Disease Activity Score in 28 joints at 6 months were found to be significantly associated with QOL improvements at the same time point.
Anti-TNF therapy is associated with improvement in both physical and mental status in PsA patients. These improvements were most substantial in patients who also had improvements in their disease activity.